P40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies

American Journal of Surgical Pathology

Volumn 38, Issue 8, 2014, Pages 1102-1110

  Henderson, Samuel A ^a   Torres Cabala, Carlos A ^a   Curry, Jonathan L ^a   Bassett, Roland L ^b   Ivan, Doina ^a   Prieto, Victor G ^a   Tetzlaff, Michael T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Atypical fibroxanthoma; p40; p63; squamous cell carcinoma

Indexed keywords

CKAP4 PROTEIN, HUMAN; EPITOPE; MEMBRANE PROTEIN; P40, IODINATED C TERMINAL PEPTIDE, HUMAN; P40, IODINATED C-TERMINAL PEPTIDE, HUMAN; PEPTIDE FRAGMENT; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DERMATOFIBROMA; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; FEMALE; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNODOMINANT EPITOPES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PEPTIDE FRAGMENTS; ROC CURVE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904467421     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000245     Document Type: Article

References (49)

1. Beer TW, Drury P, Heenan PJ. Atypical fibroxanthoma: a histological and immunohistochemical review of 171 cases. Am J Dermatopathol. 2010;32:533-540.
2. de Feraudy S, Mar N, McCalmont TH. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma. Am J Surg Pathol. 2008;32:1111-1122.
3. Fretzin DF, Helwig EB. Atypical fibroxanthoma of the skin. A clinicopathologic study of 140 cases. Cancer. 1973;31:1541-1552.
4. Luzar B, Calonje E. Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review. J Cutan Pathol. 2010;37: 301-309.
5. Mirza B, Weedon D. Atypical fibroxanthoma: a clinicopathological study of 89 cases. Australas J Dermatol. 2005;46:235-238.
6. Buonaccorsi JN, Plaza JA. Role of CD10, wide-spectrum keratin, p63, and podoplanin in the distinction of epithelioid and spindle cell tumors of the skin: an immunohistochemical study of 81 cases. Am J Dermatopathol. 2012;34:404-411.
7. Dotto JE, Glusac EJ. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2006;33: 413-417.
8. Gleason BC, Calder KB, Cibull TL, et al. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma. J Cutan Pathol. 2009;36:543-547.
9. Hall JM, Saenger JS, Fadare O. Diagnostic utility of P63 and CD10 in distinguishing cutaneous spindle cell/sarcomatoid squamous cell carcinomas and atypical fibroxanthomas. Int J Clin Exp Pathol. 2008;1:524-530.
10. Hultgren TL, DiMaio DJ. Immunohistochemical staining of CD10 in atypical fibroxanthomas. J Cutan Pathol. 2007;34:415-419.
11. Jo VY, Fletcher CD. p63 immunohistochemical staining is limited in soft tissue tumors. Am J Clin Pathol. 2011;136:762-766.
12. Kanner WA, Brill LB 2nd, Patterson JW, et al. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma. J Cutan Pathol. 2010;37:744-750.
13. Morgan MB, Purohit C, Anglin TR. Immunohistochemical distinction of cutaneous spindle cell carcinoma. Am J Dermatopathol. 2008;30:228-232.
14. Sigel JE, Skacel M, Bergfeld WF, et al. The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2001;28:520-524.
15. Wieland CN, Dyck R, Weenig RH, et al. The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma. J Cutan Pathol. 2011;38:884-888.
16. Ang GC, Roenigk RK, Otley CC, et al. More than 2 decades of treating atypical fibroxanthoma at mayo clinic: what have we learned from 91 patients? Dermatol Surg. 2009;35:765-772.
17. Broer PN, Walker ME, Goldberg C, et al. Desmoplastic melanoma: a 12-year experience with sentinel lymph node biopsy. Eur J Surg Oncol. 2013;39:681-685.
18. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one. J Cutan Pathol. 2006;33:191-206.
19. Egger ME, Huber KM, Dunki-Jacobs EM, et al. Incidence of sentinel lymph node involvement in a modern, large series of desmoplastic melanoma. J Am Coll Surg. 2013;217:37-44; discussion 44-35.
20. Schmults CD, Karia PS, Carter JB, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149:541-547.
21. Anderson PJ, McPhaden AR, Ratcliffe RJ. Atypical fibroxanthoma of the scalp. Head Neck. 2001;23:399-403.
22. Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23:759-765.
23. SeavoltM, McCall M. Atypical fibroxanthoma: review of the literature and summary of 13 patients treated with mohs micrographic surgery. Dermatol Surg. 2006;32:435-441; discussion 439-441.
24. Wick MR, Fitzgibbon J, Swanson PE. Cutaneous sarcomas and sarcomatoid neoplasms of the skin. Semin Diagn Pathol. 1993;10:148-158.
25. Prieto VG, Lugo J, McNutt NS. Intermediate- and low-molecularweight keratin detection with the monoclonal antibody MNF116. An immunohistochemical study on 232 paraffin-embedded cutaneous lesions. J Cutan Pathol. 1996;23:234-241.
26. Schmale H, Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene. 1997;15:1363-1367.
27. Trink B, Okami K, Wu L, et al. A new human p53 homologue. Nat Med. 1998;4:747-748.
28. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305-316.
29. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol. 2002;198:417-427.
30. Takeuchi Y, Tamura A, Kamiya M, et al. Immunohistochemical analyses of p63 expression in normal human skin. Br J Dermatol. 2004;151:232-235.
31. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 2001;12:337-349.
32. Nobre AR, Albergaria A, Schmitt F. p40: a p63 isoform useful for lung cancer diagnosis-a review of the physiological and pathological role of p63. Acta Cytol. 2013;57:1-8.
33. Geddert H, Kiel S, Heep HJ, et al. The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum Pathol. 2003;34:850-856.
34. Yamaguchi K, Wu L, Caballero OL, et al. Frequent gain of the p40/ p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int J Cancer. 2000;86:684-689.
35. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25:405-415.
36. Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol. 2011;6: 1039-1049.
37. Barbareschi M, Cantaloni C, Del Vescovo V, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol. 2011;136:773-782.
38. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011;117:3416-3423.
39. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
40. Koster MI, Kim S, Mills AA, et al. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004;18:126-131.
41. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8:494-501.
42. Evans HL, Smith JL. Spindle cell squamous carcinomas and sarcoma-like tumors of the skin: a comparative study of 38 cases. Cancer. 1980;45:2687-2697.
43. Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713-720.
44. Flores ER. The roles of p63 in cancer. Cell cycle. 2007;6:300-304.
45. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560-564.
46. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer cell. 2005;7:363-373.
47. Adorno M, Cordenonsi M, Montagner M, et al. A mutant-p53/ Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009;137:87-98.
48. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA. 2000;97: 5462-5467.
49. Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003;63:7113-7121.